3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
2
Phase NA
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Glioblastoma
2
Recurrence
1
Medulloblastoma
1
Glioma
1
Astrocytoma
1
Interventions
pembrolizumab
109
Paclitaxel
65
Cyclophosphamide
65
Cisplatin
60
Carboplatin
56
Gemcitabine
48
Radiotherapy
45
Nivolumab
44
fludarabine
38
Docetaxel
38
Pemetrexed
33
Dexamethasone
32
Capecitabine
32
Lenalidomide
26
fludarabine phosphate
25
Rituximab
25
Radiation
25
Ipilimumab
25
Doxorubicin
25
Irinotecan
24
Bevacizumab
24
Azacitidine
24
Vorinostat
23
Vincristine
22
Cytarabine
22
Temozolomide
20
Etoposide
20
Oxaliplatin
19
Fluorouracil
19
atezolizumab
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Has results
×
Tetanus Toxoid
×
Clear all
NCT02864368
2022-06-09
PERFORMANCE
Duke University
Phase 1
Terminated
27 enrolled
13 charts
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts